Nacuity Pharmaceuticals

Focus: Nacuity Pharmaceuticals is a Fort Worth-based biotech focused on oxidative stress treatments, primarily targeting rare neurological and ophthalmological conditions. Founded in 2017, the company operates as a pre-revenue stage biotech with a focused pipeline in high-unmet-need rare diseases.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Nacuity Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Nacuity Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Cysteamine Bitartrate

Cystinosis

Phase 1/2

Clinical Trials (1)

NCT05994534PK and PD Study of NPI-001 and Cysteamine Bitartrate

Phase 1/2

Help build intelligence for Nacuity Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead advanced-stage program: N-acetylcysteine amide in Phase 3 for Retinitis Pigmentosa represents a near-term commercialization catalyst with potential FDA approval visibility.
Rare disease focus offers meaningful clinical impact in underserved conditions (cystinosis, Usher syndromes, retinitis pigmentosa) with less competitive landscapes.
Foundational stage enables early-career scientists and operators to shape company strategy, IP development, and go-to-market approach across a compact organization.

Watch Out For

Zero active job openings and no disclosed funding/revenue data suggest a potentially tightly-staffed or capital-constrained operation with limited hiring momentum.
Pre-revenue status with all programs in Phase 1-3 means no commercial infrastructure, no revenue cushion, and execution risk across entire pipeline—liquidity and runway clarity are opaque.

Generated by Claude from Nacuity Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NPI-002 Intravitreal Implant

Cataract

Phase 1/2

Clinical Trials (1)

NCT05026632NPI-002 Intravitreal Implant for the Delay of Cataract Progression

Phase 1/2

NPI-001

Usher Syndromes

Phase 1/2

Clinical Trials (1)

NCT04355689Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

Phase 1/2

N-acetylcysteine amide

Retinitis Pigmentosa (RP)

Phase 3

Clinical Trials (1)

NCT0729053024-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2017

Portfolio: 4 clinical trials

Top TAs: Ophthalmology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Ophthalmology

1 pipeline

Marketed

Pipeline